Treatment choices for diabetic macular oedema: a guideline for when to consider an intravitreal corticosteroid, including adaptations for the COVID-19 era.

Downey, Louise; Acharya, Nachiketa; Devonport, Helen; Gale, Richard; Habib, Maged; Manjunath, Vina; Mukherjee, Rajarshi; Severn, Philip

Downey, Louise; Acharya, Nachiketa; Devonport, Helen; Gale, Richard; Habib, Maged; Manjunath, Vina; Mukherjee, Rajarshi; Severn, Philip.

Afiliação

Downey L; Department of Ophthalmology, Hull Royal Infirmary, Hull, Kingston upon Hull, UK Louise.downey@hey.nhs.uk.
Acharya N; Department of Ophthalmology, Royal Hallamshire Hospital, Sheffield, UK.
Devonport H; Department of Ophthalmology, Bradford Royal Infirmary, Bradford, UK.
Gale R; Department of Ophthalmology, York Hospital, York, UK.
Habib M; Department of Ophthalmology, Sunderland Eye Infirmary, Sunderland, UK.
Manjunath V; Department of Ophthalmology, Royal Victoria Infirmary, Newcastle upon Tyne, UK.
Mukherjee R; Department of Ophthalmology, St James's University Hospital, Leeds, UK.
Severn P; Department of Ophthalmology, James Cook University Hospital, Middlesbrough, UK.

BMJ Open Ophthalmol ; 6(1): e000696, 2021.

Article em En | MEDLINE | ID: mdl-34192155

Palavras-chave

COVID-19; drugs; inflammation; intraocular pressure; macula; retina; treatment medical; vision

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies Idioma: En Revista: BMJ Open Ophthalmol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido País de publicação: Reino Unido

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google